癌症研究里程碑,千禧年后新进展
2000年:代谢酶突变与肿瘤发生 [1]
[1] Mutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
2001年:治疗抵抗的路径 [2]
[2] Routes to resistance
(https://www.nature.com/articles/d42859-020-00069-6)
2001年:细胞周期研究获诺奖 [3]
[3] Press release: The Nobel Prize in Physiology or Medicine 2001
2003年:肥胖与肿瘤的流行病学调查 [4]
[4] Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults
2004年:首个表观遗传药物获批准上市 [5]
[5] Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes
2004年:首个抗血管药物获批上市 [6]
[6] Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
2004年:循环肿瘤细胞 [7]
[7] Routes to resistance
(https://www.nature.com/articles/d42859-020-00069-6)
2004年:治疗抵抗的路径 [8]
[8] When cancer prevention went viral
( https://www.nature.com/articles/d42859-020-00071-y )
2005年:PARP抑制剂与BRCA突变 [9]
[9] A liscence to Kill
(https://www.nature.com/articles/d42859-020-00072-x)
2005年:原癌基因诱导的细胞衰老 [10]
[10] Sitting on the Fence
(https://www.nature.com/articles/d42859-020-00073-w)
2006年:代谢只是肿瘤的一个侧面 [11]
[11] Not a simple switch
(https://www.nature.com/articles/d42859-020-00074-9)
2006年:靶向癌细胞的代谢 [12]
[12] Targeting Cancer Cell Metabolism
2007年:肿瘤免疫,无处遁形 [13]
[13] Decoding Cancer Immunology: Hunting Hidden Tumours
2007年:首款CAR-T获批上市 [14]
[14] First-Ever CAR T-cell Therapy Approved in U.S
2008年:TCGA首次发表分析结果 [15]
[15] Comprehensive genomic characterization defines human glioblastoma genes and core pathways
2008年:揭开癌症基因组的秘密 [16]
[16] Sequencing the secrets of cancer genome
(https://www.nature.com/articles/d42859-020-00075-8)
2009年:结直肠癌类器官培养 [17]
[17] Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
2009年:IDH突变产生羟戊二酸 [18]
[18] Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
2010年:CTLA-4单抗获批 [19]
[19] Unleashing the immune system against cancer(https://www.nature.com/articles/d42859-020-00076-7)
2010年:单克隆抗体治疗癌症的原理 [20]
[20] Video: Immunology Wars: Monoclonal antibodies
2010年:T细胞抗肿瘤研究继续发力 [21]
[21] Engineering armed T cells for the fight
(https://www.nature.com/articles/d42859-020-00077-6)
2010年:肿瘤免疫与免疫治疗 [22]
[22] Video: Tumor Immunology and Immunotherapy
2011年:CT早筛预防肺癌 [23]
[23] Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
2011年:免疫细胞清除衰老肿瘤细胞 [24]
[24] Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
2012年:组蛋白突变驱动肿瘤 [25]
[25] Oncohistones: epigenetic drivers of cancer
(https://www.nature.com/articles/d42859-020-00078-5)
2012年:肿瘤克隆进化 [26]
[26] Tumour evolution: from linear paths to branched trees(https://www.nature.com/articles/d42859-020-00079-4)
2012年:单细胞测序开启新纪元 [27]
[27] Full-length mRNA-Seq from single-cell levels of RNA and inpidual circulating tumor cells
2012年:丝氨酸饥饿与p53突变肿瘤 [28]
[28] Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells
2013年:谁说KRAS不可成药? [29]
[29] Undruggable? Inconceivable!
(https://www.nature.com/articles/d42859-020-00080-x)
2013年:细菌疗法治疗肿瘤 [30]
[30] Good bacteria make for good cancer therapy
(https://www.nature.com/articles/d42859-020-00081-w)
2014年:肿瘤的不平等性 [31]
[31] Video : How to tackle global inequities in cancer
2015年:肿瘤大爆炸理论 [32]
[32] A Big Bang model of human colorectal tumor growth
2015年:正常组织也含致癌突变 [33]
[33] High burden and pervasive positive selection of somatic mutations in normal human skin
2015年:细菌疗法治疗肿瘤 [34]
[34] Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma , Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
2016年:PD-L1抗体获批 [35]
[35] FDA approves new, targeted treatment for bladder cancer , Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
2017年:肿瘤领域的人工智能 (AI) [36]
[36] The AI revolution in cancer
(https://www.nature.com/articles/d42859-020-00082-9)
2017年:PD-L1抗体获批 [37]
[37] Video: Cancer, ageing, and the importance of the tumour microenvironment
2017年:PD-1抗体获批 [38]
[38] FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication ,Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
2018年:IDH2突变体抑制剂获批 [39]
[39] FDA approves new targeted treatment for relapsed or refractory acute myeloid leukemia ,Enasidenib in mutant IDH2relapsed or refractory acute myeloid leukemia
2018年:免疫疗法获得诺奖 [40]
[40] Press release: The Nobel Prize in Physiology or Medicine 2018
2019年:靶向BCMA的CAR-T展现希望 [41]
[41] Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
2019年:细胞低氧感知和适应获诺奖 [42]
[42] Press release: The Nobel Prize in Physiology or Medicine 2019
2019年:TCGA综合分析结果发表 [43]
[43] Pan-cancer analysis of whole genomes
2020年:CAR-NK 临床实验表现积极 [44]
[44] Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
2020年:CAR-M 初现曙光 [45]
[45] Human chimeric antigen receptor macrophages for cancer immunotherapy
2020年:诺奖授予丙肝病毒研究 [46]
[46] Press release: The Nobel Prize in Physiology or Medicine 2020
2020年:诺奖授予CRISPR-Cas9 [47]
[47] Press release: The Nobel Prize in Chemistry 2020
参考资料:
https://www.nobelprize.org/prizes/lists/all-nobel-prizes/
https://www.nature.com/immersive/d42859-020-00083-8/index.html
链接:http://www.lewenyixue.com/2024/12/25/%E7%99%8C%E7%97%87%E7%A0%94%E7%A9%B6%E9%87%8C%E7%A8%8B%E7%A2%91%EF%BC%8C%E5%8D%83%E7%A6%A7%E5%B9%B4%E5%90%8E%E6%96%B0%E8%BF%9B%E5%B1%95/